TY - JOUR
T1 - Sprouty2 drives drug resistance and proliferation in Glioblastoma
AU - Walsh, Alice M.
AU - Kapoor, Gurpreet S.
AU - Buonato, Janine M.
AU - Mathew, Lijoy K.
AU - Bi, Yingtao
AU - Davuluri, Ramana V.
AU - Martinez-Lage, Maria
AU - Simon, M. Celeste
AU - O'Rourke, Donald M.
AU - Lazzara, Matthew J.
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Glioblastoma multiforme (GBM) is notoriously resistant to therapy, and the development of a durable cure will require the identification of broadly relevant regulators of GBM cell tumorigenicity and survival. Here, we identify Sprouty2(SPRY2), a known regulator of receptor tyrosine kinases (RTK), as one such regulator. SPRY2 knockdown reduced proliferation and anchorageindependent growth in GBM cells and slowed xenograft tumor growth in mice. SPRY2 knockdown also promoted cell death in response to coinhibition of the epidermal growth factor receptor (EGFR) and the c-MET receptor in GBM cells, an effect that involved regulation of the ability of the p38 mitogen-activated protein kinase (MAPK) to drive cell death in response to inhibitors. Analysis of data from clinical tumor specimens further demonstrated that SPRY2 protein is definitively expressed in GBM tissue, that SPRY2 expression is elevated in GBM tumors expressing EGFR variant III (EGFRvIII), and that elevated SPRY2 mRNA expression portends reduced GBM patient survival. Overall, these results identify SPRY2 and the pathways it regulates as novel candidate biomarkers and therapeutic targets in GBM. Implications: SPRY2, counter to its roles in other cancer settings, promotes glioma cell and tumor growth and cellular resistance to targeted inhibitors of oncogenic RTKs, thus making SPRY2 and the cell signaling processes it regulates potential novel therapeutic targets in glioma.
AB - Glioblastoma multiforme (GBM) is notoriously resistant to therapy, and the development of a durable cure will require the identification of broadly relevant regulators of GBM cell tumorigenicity and survival. Here, we identify Sprouty2(SPRY2), a known regulator of receptor tyrosine kinases (RTK), as one such regulator. SPRY2 knockdown reduced proliferation and anchorageindependent growth in GBM cells and slowed xenograft tumor growth in mice. SPRY2 knockdown also promoted cell death in response to coinhibition of the epidermal growth factor receptor (EGFR) and the c-MET receptor in GBM cells, an effect that involved regulation of the ability of the p38 mitogen-activated protein kinase (MAPK) to drive cell death in response to inhibitors. Analysis of data from clinical tumor specimens further demonstrated that SPRY2 protein is definitively expressed in GBM tissue, that SPRY2 expression is elevated in GBM tumors expressing EGFR variant III (EGFRvIII), and that elevated SPRY2 mRNA expression portends reduced GBM patient survival. Overall, these results identify SPRY2 and the pathways it regulates as novel candidate biomarkers and therapeutic targets in GBM. Implications: SPRY2, counter to its roles in other cancer settings, promotes glioma cell and tumor growth and cellular resistance to targeted inhibitors of oncogenic RTKs, thus making SPRY2 and the cell signaling processes it regulates potential novel therapeutic targets in glioma.
UR - http://www.scopus.com/inward/record.url?scp=84942415396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942415396&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-14-0183-T
DO - 10.1158/1541-7786.MCR-14-0183-T
M3 - Article
C2 - 25934697
AN - SCOPUS:84942415396
SN - 1541-7786
VL - 13
SP - 1227
EP - 1237
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 8
ER -